Home Event Modulating the androgen receptor as a therapeutic strategy for estrogen receptor-positive breast cancer using patient-derived xenografts  | Exploring the potential of a novel HER3-targeted antibody-drug conjugate in breast cancer patient-derived xenografts

Date

01 Jul 2021
Expired!

Time

9:30 am - 10:30 am

Modulating the androgen receptor as a therapeutic strategy for estrogen receptor-positive breast cancer using patient-derived xenografts  | Exploring the potential of a novel HER3-targeted antibody-drug conjugate in breast cancer patient-derived xenografts

First part

  • Invited Speaker: Laia Monserrat, PhD student in Experimental Therapeutics group (headed by Dra. Violeta Serra)
  • Talk title: Modulating the androgen receptor as a therapeutic strategy for estrogen receptor-positive breast cancer using patient-derived xenografts

Recent studies suggest that the androgen receptor (AR) has a protective role in estrogen receptor (ER) positive breast cancer. It has been recently discovered that a novel drug activating the AR can influence the activity of the ER. In the present project we aim to identify biomarkers of response to a novel AR modulator in ER+ breast cancer patient-derived xenografts and its potential application in combination with CDK4/6 inhibitors in the metastatic setting

Second part

  • Invited Speaker: Andreu Òdena, Master’s student in Experimental Therapeutics group (headed by Dra. Violeta Serra)
  • Title: Exploring the potential of a novel HER3-targeted antibody-drug conjugate in breast cancer patient-derived xenografts

HER3 is overexpressed in 30-50% of breast cancers and it has been associated with poor prognosis. Patritumab deruxtecan (U3-1402) is a novel HER3-targeted ADC with a potent topoisomerase I (TOP1) inhibitor payload that has emerged as a promising new targeted therapy for many types of cancers. In this project we aim to evaluate the antitumor activity of this new therapy in breast cancer patient-derived xenografts and to identify biomarkers of response to this novel ADC that could contribute to select patients for this treatment strategy.